| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 152 | 2024 | 622 | 36.920 |
Why?
|
| Uric Acid | 89 | 2024 | 809 | 14.930 |
Why?
|
| Hyperuricemia | 54 | 2024 | 222 | 13.660 |
Why?
|
| Gout Suppressants | 45 | 2024 | 176 | 10.040 |
Why?
|
| Allopurinol | 26 | 2024 | 203 | 7.490 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 14 | 2024 | 238 | 3.830 |
Why?
|
| Hydroxychloroquine | 10 | 2024 | 427 | 3.780 |
Why?
|
| Antirheumatic Agents | 28 | 2024 | 1383 | 3.150 |
Why?
|
| Arthritis, Rheumatoid | 49 | 2023 | 3788 | 3.010 |
Why?
|
| Chondrocalcinosis | 9 | 2024 | 84 | 2.970 |
Why?
|
| Lupus Erythematosus, Systemic | 13 | 2024 | 2160 | 2.670 |
Why?
|
| Rheumatology | 10 | 2023 | 619 | 2.630 |
Why?
|
| Arthritis, Psoriatic | 16 | 2021 | 219 | 2.550 |
Why?
|
| Rheumatic Diseases | 13 | 2022 | 658 | 2.200 |
Why?
|
| Arthritis, Gouty | 7 | 2021 | 28 | 2.010 |
Why?
|
| Nutrition Surveys | 21 | 2023 | 1737 | 1.990 |
Why?
|
| Psoriasis | 17 | 2021 | 925 | 1.950 |
Why?
|
| Diuretics | 9 | 2020 | 614 | 1.800 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 15 | 2023 | 297 | 1.790 |
Why?
|
| Incidence | 74 | 2024 | 21525 | 1.760 |
Why?
|
| Retinal Diseases | 5 | 2024 | 709 | 1.720 |
Why?
|
| Middle Aged | 231 | 2024 | 223257 | 1.690 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 220 | 1.600 |
Why?
|
| British Columbia | 22 | 2024 | 239 | 1.590 |
Why?
|
| Cohort Studies | 88 | 2024 | 41710 | 1.550 |
Why?
|
| Calcium Pyrophosphate | 7 | 2024 | 55 | 1.480 |
Why?
|
| Humans | 404 | 2024 | 766766 | 1.480 |
Why?
|
| Male | 259 | 2024 | 364142 | 1.470 |
Why?
|
| Hospitalization | 17 | 2024 | 10823 | 1.450 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2024 | 317 | 1.410 |
Why?
|
| Cause of Death | 16 | 2024 | 3716 | 1.400 |
Why?
|
| Databases, Factual | 34 | 2024 | 8066 | 1.390 |
Why?
|
| Female | 257 | 2024 | 396520 | 1.370 |
Why?
|
| Kidney Failure, Chronic | 9 | 2023 | 2505 | 1.370 |
Why?
|
| Risk Factors | 115 | 2024 | 74881 | 1.360 |
Why?
|
| Aged | 165 | 2024 | 171343 | 1.360 |
Why?
|
| Myocardial Infarction | 23 | 2023 | 11513 | 1.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 12245 | 1.320 |
Why?
|
| Pulmonary Embolism | 10 | 2023 | 2596 | 1.320 |
Why?
|
| Venous Thrombosis | 10 | 2021 | 1321 | 1.310 |
Why?
|
| Fructose | 6 | 2011 | 284 | 1.280 |
Why?
|
| Hypertension | 24 | 2024 | 8616 | 1.220 |
Why?
|
| Alcohol Drinking | 19 | 2024 | 4045 | 1.170 |
Why?
|
| Calcinosis | 4 | 2023 | 1480 | 1.160 |
Why?
|
| Glucocorticoids | 11 | 2024 | 2158 | 1.150 |
Why?
|
| Polymyositis | 4 | 2021 | 75 | 1.140 |
Why?
|
| Lupus Nephritis | 3 | 2022 | 324 | 1.130 |
Why?
|
| Proportional Hazards Models | 39 | 2024 | 12534 | 1.120 |
Why?
|
| Cardiovascular Diseases | 25 | 2024 | 15657 | 1.120 |
Why?
|
| Adult | 161 | 2024 | 223307 | 1.110 |
Why?
|
| Obesity | 21 | 2021 | 13090 | 1.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2018 | 3250 | 1.090 |
Why?
|
| Mendelian Randomization Analysis | 7 | 2024 | 1044 | 1.080 |
Why?
|
| Drug Eruptions | 2 | 2019 | 335 | 1.010 |
Why?
|
| Penicillins | 2 | 2019 | 404 | 1.000 |
Why?
|
| United States | 76 | 2024 | 72951 | 1.000 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2024 | 2306 | 0.980 |
Why?
|
| Giant Cell Arteritis | 6 | 2017 | 308 | 0.970 |
Why?
|
| Peroxidase | 6 | 2020 | 610 | 0.970 |
Why?
|
| Benzbromarone | 1 | 2024 | 7 | 0.950 |
Why?
|
| Diet | 23 | 2023 | 8088 | 0.930 |
Why?
|
| Dermatomyositis | 4 | 2021 | 259 | 0.920 |
Why?
|
| Recurrence | 15 | 2024 | 8507 | 0.920 |
Why?
|
| Ophthalmology | 3 | 2022 | 560 | 0.920 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 746 | 0.910 |
Why?
|
| Comorbidity | 24 | 2024 | 10580 | 0.910 |
Why?
|
| Colchicine | 4 | 2021 | 257 | 0.890 |
Why?
|
| Life Style | 12 | 2021 | 3926 | 0.890 |
Why?
|
| Body Mass Index | 29 | 2021 | 13050 | 0.880 |
Why?
|
| Remission Induction | 10 | 2023 | 2413 | 0.850 |
Why?
|
| Urolithiasis | 1 | 2024 | 123 | 0.840 |
Why?
|
| Nephrolithiasis | 1 | 2024 | 117 | 0.830 |
Why?
|
| Risk | 21 | 2023 | 9602 | 0.830 |
Why?
|
| Venous Thromboembolism | 11 | 2022 | 1882 | 0.830 |
Why?
|
| Population Surveillance | 5 | 2019 | 2594 | 0.830 |
Why?
|
| Beverages | 7 | 2011 | 819 | 0.820 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 18075 | 0.810 |
Why?
|
| Histone Deacetylases | 5 | 2018 | 712 | 0.800 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 346 | 0.790 |
Why?
|
| Apoptosis Regulatory Proteins | 6 | 2018 | 1150 | 0.770 |
Why?
|
| Spondylitis, Ankylosing | 3 | 2019 | 158 | 0.760 |
Why?
|
| Case-Control Studies | 41 | 2024 | 22248 | 0.750 |
Why?
|
| Alcoholic Beverages | 4 | 2010 | 266 | 0.740 |
Why?
|
| beta Carotene | 2 | 2013 | 523 | 0.740 |
Why?
|
| Prevalence | 24 | 2023 | 15835 | 0.740 |
Why?
|
| Drug Dosage Calculations | 2 | 2018 | 116 | 0.730 |
Why?
|
| Prospective Studies | 48 | 2024 | 54871 | 0.720 |
Why?
|
| Xanthine Oxidase | 2 | 2018 | 69 | 0.710 |
Why?
|
| Diabetes Mellitus | 11 | 2021 | 5887 | 0.710 |
Why?
|
| Follow-Up Studies | 35 | 2024 | 39309 | 0.710 |
Why?
|
| Stevens-Johnson Syndrome | 3 | 2020 | 231 | 0.690 |
Why?
|
| Drug Hypersensitivity | 2 | 2019 | 903 | 0.680 |
Why?
|
| Cost of Illness | 6 | 2017 | 1949 | 0.680 |
Why?
|
| Coffee | 4 | 2010 | 594 | 0.680 |
Why?
|
| Neoplasm Proteins | 10 | 2024 | 3601 | 0.660 |
Why?
|
| Vitamin A | 2 | 2013 | 611 | 0.660 |
Why?
|
| Knee Joint | 6 | 2023 | 1682 | 0.660 |
Why?
|
| Foot Joints | 1 | 2019 | 34 | 0.650 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 49 | 0.650 |
Why?
|
| Stroke | 12 | 2023 | 9741 | 0.640 |
Why?
|
| Joints | 3 | 2019 | 324 | 0.630 |
Why?
|
| Tramadol | 4 | 2020 | 63 | 0.630 |
Why?
|
| Health Occupations | 1 | 2020 | 226 | 0.630 |
Why?
|
| Hand Joints | 1 | 2019 | 58 | 0.630 |
Why?
|
| Herpes Zoster | 2 | 2019 | 252 | 0.620 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 12064 | 0.610 |
Why?
|
| Amino Acids | 1 | 2024 | 1711 | 0.600 |
Why?
|
| Dairy Products | 4 | 2006 | 490 | 0.600 |
Why?
|
| Hypoglycemic Agents | 5 | 2024 | 3108 | 0.600 |
Why?
|
| Uricosuric Agents | 4 | 2024 | 30 | 0.600 |
Why?
|
| Osteoarthritis | 8 | 2019 | 1072 | 0.600 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 328 | 0.590 |
Why?
|
| Kidney Transplantation | 5 | 2022 | 4278 | 0.580 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2020 | 263 | 0.580 |
Why?
|
| Eye Diseases | 2 | 2022 | 660 | 0.570 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 811 | 0.570 |
Why?
|
| Sex Factors | 15 | 2021 | 10619 | 0.560 |
Why?
|
| Immunoglobulin G | 11 | 2023 | 4559 | 0.560 |
Why?
|
| Biological Products | 4 | 2021 | 948 | 0.550 |
Why?
|
| Dietary Fiber | 1 | 2021 | 767 | 0.550 |
Why?
|
| Ascorbic Acid | 3 | 2009 | 658 | 0.550 |
Why?
|
| Osteoarthritis, Knee | 8 | 2022 | 1251 | 0.540 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 2 | 2013 | 28 | 0.540 |
Why?
|
| Phenylacetates | 1 | 2016 | 112 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2024 | 20708 | 0.530 |
Why?
|
| Smoking | 12 | 2021 | 9077 | 0.530 |
Why?
|
| Cross-Over Studies | 9 | 2024 | 2108 | 0.530 |
Why?
|
| Metformin | 1 | 2024 | 908 | 0.530 |
Why?
|
| Insurance Claim Review | 2 | 2024 | 744 | 0.520 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2019 | 2270 | 0.520 |
Why?
|
| Risk Assessment | 30 | 2024 | 24295 | 0.520 |
Why?
|
| Apathy | 1 | 2017 | 107 | 0.510 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 1120 | 0.510 |
Why?
|
| Health Expenditures | 3 | 2020 | 2390 | 0.500 |
Why?
|
| Purines | 4 | 2012 | 615 | 0.490 |
Why?
|
| Artifacts | 1 | 2024 | 1896 | 0.490 |
Why?
|
| Autoimmune Diseases | 5 | 2022 | 2254 | 0.480 |
Why?
|
| Sjogren's Syndrome | 1 | 2017 | 240 | 0.480 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2024 | 16044 | 0.480 |
Why?
|
| Health Care Costs | 3 | 2024 | 3242 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2017 | 2948 | 0.480 |
Why?
|
| Erectile Dysfunction | 1 | 2018 | 437 | 0.480 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 59550 | 0.470 |
Why?
|
| Glucose Transport Proteins, Facilitative | 5 | 2024 | 58 | 0.470 |
Why?
|
| Acetamides | 1 | 2016 | 260 | 0.470 |
Why?
|
| Propensity Score | 9 | 2024 | 1972 | 0.470 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 849 | 0.460 |
Why?
|
| Cardiovascular System | 2 | 2020 | 839 | 0.460 |
Why?
|
| Commerce | 1 | 2020 | 614 | 0.460 |
Why?
|
| General Practice | 1 | 2015 | 101 | 0.450 |
Why?
|
| Cost-Benefit Analysis | 6 | 2017 | 5536 | 0.440 |
Why?
|
| Registries | 8 | 2024 | 8351 | 0.440 |
Why?
|
| Dietary Proteins | 3 | 2020 | 960 | 0.440 |
Why?
|
| Myocardial Ischemia | 4 | 2023 | 2132 | 0.440 |
Why?
|
| Sex Distribution | 9 | 2021 | 2274 | 0.430 |
Why?
|
| Canada | 4 | 2024 | 2126 | 0.430 |
Why?
|
| Prunus | 1 | 2012 | 12 | 0.420 |
Why?
|
| Caffeine | 3 | 2024 | 702 | 0.420 |
Why?
|
| Meat | 3 | 2005 | 588 | 0.420 |
Why?
|
| Primary Prevention | 1 | 2020 | 1188 | 0.420 |
Why?
|
| Eating | 3 | 2021 | 1539 | 0.410 |
Why?
|
| Immunologic Factors | 2 | 2019 | 1594 | 0.410 |
Why?
|
| Insulin Resistance | 4 | 2021 | 3989 | 0.410 |
Why?
|
| Menopause | 3 | 2010 | 1657 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2009 | 1205 | 0.400 |
Why?
|
| Survival Rate | 8 | 2017 | 12825 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2024 | 10745 | 0.390 |
Why?
|
| DNA Damage | 4 | 2017 | 2467 | 0.390 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 705 | 0.380 |
Why?
|
| Arthritis, Infectious | 1 | 2015 | 347 | 0.380 |
Why?
|
| Feeding Behavior | 7 | 2014 | 3208 | 0.380 |
Why?
|
| Methotrexate | 6 | 2023 | 1719 | 0.370 |
Why?
|
| Clostridium Infections | 1 | 2018 | 563 | 0.370 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1880 | 0.370 |
Why?
|
| Sweetening Agents | 2 | 2010 | 291 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 3230 | 0.360 |
Why?
|
| United States Food and Drug Administration | 4 | 2021 | 1673 | 0.360 |
Why?
|
| Hospital Costs | 1 | 2017 | 955 | 0.360 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2024 | 105 | 0.360 |
Why?
|
| Decision Support Techniques | 5 | 2016 | 2006 | 0.360 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 482 | 0.360 |
Why?
|
| Mortality | 6 | 2019 | 2910 | 0.360 |
Why?
|
| Vaccines | 1 | 2019 | 842 | 0.360 |
Why?
|
| Republic of Korea | 5 | 2024 | 591 | 0.350 |
Why?
|
| Casein Kinase II | 4 | 2017 | 121 | 0.350 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2014 | 488 | 0.350 |
Why?
|
| Diet Surveys | 6 | 2023 | 1159 | 0.340 |
Why?
|
| Managed Care Programs | 1 | 2015 | 935 | 0.330 |
Why?
|
| Medicaid | 2 | 2021 | 2836 | 0.330 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 541 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 4 | 2022 | 7431 | 0.330 |
Why?
|
| Naproxen | 4 | 2019 | 101 | 0.330 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 26310 | 0.330 |
Why?
|
| Logistic Models | 12 | 2024 | 13278 | 0.330 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 1396 | 0.320 |
Why?
|
| Severity of Illness Index | 20 | 2020 | 15908 | 0.320 |
Why?
|
| Epidemiologic Methods | 7 | 2011 | 1326 | 0.320 |
Why?
|
| Research Design | 4 | 2017 | 6207 | 0.320 |
Why?
|
| Age Distribution | 8 | 2020 | 2869 | 0.320 |
Why?
|
| Pilot Projects | 4 | 2021 | 8728 | 0.320 |
Why?
|
| Tea | 2 | 2007 | 289 | 0.310 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 2234 | 0.310 |
Why?
|
| Genome-Wide Association Study | 16 | 2024 | 12806 | 0.310 |
Why?
|
| Odds Ratio | 13 | 2021 | 9661 | 0.310 |
Why?
|
| Coronary Disease | 4 | 2019 | 5915 | 0.310 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 4215 | 0.300 |
Why?
|
| Women | 1 | 2010 | 225 | 0.300 |
Why?
|
| Probenecid | 2 | 2019 | 72 | 0.300 |
Why?
|
| Age Factors | 13 | 2019 | 18397 | 0.300 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3721 | 0.290 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 2334 | 0.290 |
Why?
|
| Retrospective Studies | 30 | 2024 | 81635 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2020 | 3446 | 0.290 |
Why?
|
| Vegetables | 3 | 2021 | 1199 | 0.290 |
Why?
|
| Protein Kinases | 1 | 2014 | 1610 | 0.290 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3411 | 0.280 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 982 | 0.280 |
Why?
|
| Young Adult | 23 | 2021 | 59939 | 0.280 |
Why?
|
| Urate Oxidase | 3 | 2024 | 33 | 0.280 |
Why?
|
| Spondylarthritis | 2 | 2018 | 62 | 0.280 |
Why?
|
| Arthritis | 3 | 2024 | 684 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2022 | 10384 | 0.270 |
Why?
|
| Syndrome | 2 | 2023 | 3271 | 0.270 |
Why?
|
| Vaccination | 1 | 2019 | 3434 | 0.270 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 550 | 0.270 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2007 | 202 | 0.270 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2007 | 127 | 0.270 |
Why?
|
| Medicare | 4 | 2022 | 6820 | 0.270 |
Why?
|
| Body Weight | 5 | 2018 | 4626 | 0.260 |
Why?
|
| Treatment Outcome | 26 | 2024 | 65273 | 0.260 |
Why?
|
| Time Factors | 15 | 2021 | 40149 | 0.260 |
Why?
|
| Lipids | 3 | 2005 | 3319 | 0.250 |
Why?
|
| Fruit | 2 | 2021 | 1166 | 0.250 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1791 | 0.240 |
Why?
|
| Longitudinal Studies | 15 | 2024 | 14762 | 0.240 |
Why?
|
| Myeloblastin | 4 | 2019 | 101 | 0.240 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2015 | 85 | 0.240 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 1474 | 0.240 |
Why?
|
| Cholesterol, HDL | 7 | 2019 | 1812 | 0.240 |
Why?
|
| Fibroblasts | 1 | 2015 | 4166 | 0.230 |
Why?
|
| Weight Loss | 2 | 2020 | 2712 | 0.230 |
Why?
|
| Genetic Loci | 4 | 2021 | 2630 | 0.230 |
Why?
|
| Cholesterol | 8 | 2021 | 2903 | 0.230 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 996 | 0.220 |
Why?
|
| Death Certificates | 1 | 2024 | 172 | 0.220 |
Why?
|
| Polyethylene Glycols | 3 | 2024 | 1189 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7475 | 0.220 |
Why?
|
| Prognosis | 12 | 2021 | 29948 | 0.220 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2024 | 89 | 0.220 |
Why?
|
| Heart Failure | 4 | 2024 | 11882 | 0.220 |
Why?
|
| Lactones | 2 | 2016 | 316 | 0.220 |
Why?
|
| Waiting Lists | 2 | 2019 | 779 | 0.220 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 7871 | 0.220 |
Why?
|
| Health Behavior | 2 | 2017 | 2649 | 0.220 |
Why?
|
| Antioxidants | 2 | 2008 | 1671 | 0.220 |
Why?
|
| Genetic Testing | 1 | 2016 | 3591 | 0.210 |
Why?
|
| Hip Fractures | 3 | 2023 | 996 | 0.210 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 2593 | 0.210 |
Why?
|
| Actuarial Analysis | 1 | 2003 | 370 | 0.210 |
Why?
|
| Insulin | 5 | 2024 | 6608 | 0.210 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 1292 | 0.210 |
Why?
|
| Sodium, Dietary | 2 | 2016 | 426 | 0.210 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5343 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4349 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2007 | 698 | 0.210 |
Why?
|
| Patient Compliance | 1 | 2013 | 2694 | 0.210 |
Why?
|
| New Zealand | 3 | 2017 | 360 | 0.210 |
Why?
|
| Transcriptional Activation | 2 | 2014 | 1749 | 0.210 |
Why?
|
| Fractures, Bone | 3 | 2017 | 2043 | 0.200 |
Why?
|
| Phosphorylation | 6 | 2018 | 8307 | 0.200 |
Why?
|
| Systemic Vasculitis | 1 | 2023 | 37 | 0.200 |
Why?
|
| Codeine | 2 | 2019 | 52 | 0.200 |
Why?
|
| Diet, Vegetarian | 1 | 2024 | 181 | 0.200 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2024 | 386 | 0.200 |
Why?
|
| Xenopus laevis | 2 | 2024 | 965 | 0.200 |
Why?
|
| Choice Behavior | 2 | 2005 | 846 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.200 |
Why?
|
| Markov Chains | 4 | 2017 | 974 | 0.200 |
Why?
|
| Genetic Markers | 2 | 2020 | 2603 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 723 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2030 | 0.200 |
Why?
|
| Obesity, Abdominal | 2 | 2019 | 371 | 0.200 |
Why?
|
| Sulfasalazine | 1 | 2002 | 85 | 0.200 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2019 | 1389 | 0.200 |
Why?
|
| Sensitivity and Specificity | 10 | 2019 | 14652 | 0.190 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2024 | 566 | 0.190 |
Why?
|
| Quantitative Trait Loci | 2 | 2020 | 2136 | 0.190 |
Why?
|
| Europe | 6 | 2019 | 3430 | 0.190 |
Why?
|
| California | 2 | 2024 | 1435 | 0.190 |
Why?
|
| Araliaceae | 1 | 2021 | 1 | 0.190 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 970 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 588 | 0.190 |
Why?
|
| Stomatitis | 1 | 2024 | 271 | 0.190 |
Why?
|
| Ambulatory Care | 1 | 2012 | 2779 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 1404 | 0.180 |
Why?
|
| Epidemiologic Research Design | 1 | 2004 | 368 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1885 | 0.180 |
Why?
|
| Aspirin | 1 | 2013 | 3135 | 0.180 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 2727 | 0.180 |
Why?
|
| Thiazines | 2 | 2017 | 38 | 0.180 |
Why?
|
| Otorhinolaryngologic Diseases | 2 | 2019 | 97 | 0.180 |
Why?
|
| Informatics | 1 | 2021 | 72 | 0.180 |
Why?
|
| Arthralgia | 2 | 2022 | 459 | 0.180 |
Why?
|
| Vitamins | 1 | 2009 | 1631 | 0.180 |
Why?
|
| Isoxazoles | 1 | 2002 | 233 | 0.180 |
Why?
|
| Plant Leaves | 1 | 2021 | 153 | 0.180 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2015 | 637 | 0.170 |
Why?
|
| IgG Deficiency | 1 | 2020 | 28 | 0.170 |
Why?
|
| Thiazoles | 3 | 2017 | 1529 | 0.170 |
Why?
|
| Biology | 1 | 2022 | 292 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 10100 | 0.170 |
Why?
|
| HCT116 Cells | 3 | 2015 | 401 | 0.170 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 402 | 0.170 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.170 |
Why?
|
| Adenosine | 1 | 2024 | 813 | 0.160 |
Why?
|
| Crystallization | 2 | 2014 | 518 | 0.160 |
Why?
|
| Consensus | 5 | 2022 | 3208 | 0.160 |
Why?
|
| Mikulicz' Disease | 1 | 2019 | 8 | 0.160 |
Why?
|
| Health Status | 4 | 2009 | 4087 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 755 | 0.160 |
Why?
|
| Azathioprine | 4 | 2023 | 354 | 0.160 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 836 | 0.160 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2024 | 61 | 0.160 |
Why?
|
| Repressor Proteins | 3 | 2016 | 2978 | 0.160 |
Why?
|
| Bone Malalignment | 1 | 2018 | 38 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 282 | 0.160 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2019 | 42 | 0.160 |
Why?
|
| Japan | 2 | 2024 | 1417 | 0.160 |
Why?
|
| Triglycerides | 5 | 2010 | 2441 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 1168 | 0.150 |
Why?
|
| Disease Management | 3 | 2018 | 2533 | 0.150 |
Why?
|
| Ubiquitination | 4 | 2015 | 1007 | 0.150 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2017 | 319 | 0.150 |
Why?
|
| Organic Anion Transporters | 2 | 2024 | 101 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 2017 | 1406 | 0.150 |
Why?
|
| Health Personnel | 5 | 2017 | 3384 | 0.150 |
Why?
|
| Apolipoprotein A-I | 3 | 2019 | 305 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 594 | 0.150 |
Why?
|
| Israel | 1 | 2020 | 726 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2022 | 554 | 0.150 |
Why?
|
| Health Resources | 1 | 2024 | 951 | 0.150 |
Why?
|
| Nutrition Policy | 1 | 2022 | 467 | 0.150 |
Why?
|
| Aortitis | 1 | 2019 | 77 | 0.150 |
Why?
|
| Enzyme Activation | 2 | 2014 | 3587 | 0.150 |
Why?
|
| Sodium | 1 | 2023 | 1594 | 0.150 |
Why?
|
| Adolescent | 17 | 2021 | 88904 | 0.150 |
Why?
|
| Random Allocation | 1 | 2022 | 2394 | 0.150 |
Why?
|
| Pain | 2 | 2023 | 5098 | 0.150 |
Why?
|
| Diclofenac | 4 | 2019 | 68 | 0.140 |
Why?
|
| Parkinson Disease | 2 | 2008 | 2884 | 0.140 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 241 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2021 | 496 | 0.140 |
Why?
|
| Dermatologic Agents | 1 | 2021 | 314 | 0.140 |
Why?
|
| Overweight | 3 | 2019 | 2446 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2020 | 541 | 0.140 |
Why?
|
| C-Reactive Protein | 5 | 2022 | 3853 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 5368 | 0.140 |
Why?
|
| Digestive System Diseases | 1 | 2019 | 152 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2004 | 1249 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 2019 | 620 | 0.140 |
Why?
|
| Agammaglobulinemia | 1 | 2018 | 173 | 0.140 |
Why?
|
| Sulfinpyrazone | 1 | 2016 | 15 | 0.140 |
Why?
|
| Diet, Reducing | 1 | 2020 | 487 | 0.140 |
Why?
|
| Cell Line, Tumor | 12 | 2016 | 17088 | 0.140 |
Why?
|
| Nurses | 4 | 2021 | 2503 | 0.140 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 11094 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 834 | 0.140 |
Why?
|
| Drinking Behavior | 2 | 2007 | 102 | 0.140 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2016 | 82 | 0.130 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 792 | 0.130 |
Why?
|
| Transducin | 1 | 2016 | 42 | 0.130 |
Why?
|
| Patients | 1 | 2003 | 908 | 0.130 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 609 | 0.130 |
Why?
|
| Population Growth | 1 | 2016 | 50 | 0.130 |
Why?
|
| Quality of Life | 7 | 2021 | 13476 | 0.130 |
Why?
|
| Prehypertension | 1 | 2016 | 63 | 0.130 |
Why?
|
| Analgesics, Opioid | 4 | 2020 | 3837 | 0.130 |
Why?
|
| Clinical Coding | 2 | 2016 | 187 | 0.130 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.130 |
Why?
|
| Hydrolyzable Tannins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Hand | 2 | 2015 | 909 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 2228 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2017 | 507 | 0.130 |
Why?
|
| Disease Progression | 5 | 2019 | 13640 | 0.130 |
Why?
|
| Sumoylation | 1 | 2016 | 83 | 0.130 |
Why?
|
| Co-Repressor Proteins | 2 | 2013 | 190 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2019 | 1540 | 0.130 |
Why?
|
| Electronic Health Records | 4 | 2024 | 4880 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2823 | 0.130 |
Why?
|
| Drugs, Generic | 1 | 2021 | 457 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2023 | 2201 | 0.120 |
Why?
|
| Hyperlipidemias | 2 | 2018 | 771 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2017 | 327 | 0.120 |
Why?
|
| Metabolomics | 1 | 2024 | 1675 | 0.120 |
Why?
|
| Caspase 7 | 1 | 2014 | 51 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2019 | 892 | 0.120 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2016 | 291 | 0.120 |
Why?
|
| Weight Gain | 1 | 2005 | 2356 | 0.120 |
Why?
|
| Acetylation | 2 | 2014 | 1054 | 0.120 |
Why?
|
| Karyopherins | 1 | 2015 | 134 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4853 | 0.120 |
Why?
|
| HeLa Cells | 2 | 2013 | 3073 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2023 | 1621 | 0.120 |
Why?
|
| Wrist Injuries | 1 | 2017 | 215 | 0.110 |
Why?
|
| Joint Diseases | 1 | 2018 | 461 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 610 | 0.110 |
Why?
|
| Lysophospholipase | 1 | 2014 | 66 | 0.110 |
Why?
|
| Cytoplasm | 2 | 2019 | 1505 | 0.110 |
Why?
|
| Magnesium | 1 | 2017 | 815 | 0.110 |
Why?
|
| Rheumatoid Factor | 2 | 2005 | 185 | 0.110 |
Why?
|
| Vasculitis | 3 | 2003 | 528 | 0.110 |
Why?
|
| Knee Injuries | 1 | 2018 | 495 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2013 | 432 | 0.110 |
Why?
|
| Radiography | 6 | 2023 | 6968 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 820 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 1895 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 2456 | 0.110 |
Why?
|
| Gallstones | 1 | 2016 | 285 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 8717 | 0.110 |
Why?
|
| Humidity | 1 | 2014 | 206 | 0.110 |
Why?
|
| Glucose | 2 | 2023 | 4340 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2017 | 6612 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 874 | 0.100 |
Why?
|
| Catechin | 1 | 2013 | 69 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 9611 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2013 | 144 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1169 | 0.100 |
Why?
|
| Smad3 Protein | 1 | 2013 | 165 | 0.100 |
Why?
|
| Protein Binding | 6 | 2015 | 9320 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 446 | 0.100 |
Why?
|
| Kidney | 4 | 2023 | 7074 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 856 | 0.100 |
Why?
|
| Blood Sedimentation | 3 | 2019 | 234 | 0.100 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 351 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 588 | 0.100 |
Why?
|
| Selection Bias | 1 | 2014 | 359 | 0.100 |
Why?
|
| Disability Evaluation | 4 | 2009 | 1827 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2020 | 2101 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 1597 | 0.100 |
Why?
|
| Linear Models | 3 | 2019 | 5874 | 0.100 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 4424 | 0.100 |
Why?
|
| Signal Transduction | 9 | 2016 | 23619 | 0.100 |
Why?
|
| Kallikreins | 1 | 2013 | 219 | 0.100 |
Why?
|
| Consanguinity | 1 | 2014 | 460 | 0.100 |
Why?
|
| Animals | 18 | 2024 | 168930 | 0.100 |
Why?
|
| Patient Care Team | 2 | 2020 | 2519 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 857 | 0.100 |
Why?
|
| Phenotype | 4 | 2024 | 16724 | 0.100 |
Why?
|
| Cooking | 1 | 2014 | 327 | 0.100 |
Why?
|
| Adiposity | 1 | 2021 | 1892 | 0.100 |
Why?
|
| Transfection | 3 | 2014 | 5754 | 0.100 |
Why?
|
| Blood Pressure | 3 | 2016 | 8533 | 0.100 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 2 | 2024 | 28 | 0.090 |
Why?
|
| Inflammation | 5 | 2024 | 10860 | 0.090 |
Why?
|
| Cartilage, Articular | 1 | 2019 | 1104 | 0.090 |
Why?
|
| Wrist Joint | 2 | 2024 | 266 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2020 | 2115 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 2012 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2017 | 1964 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 987 | 0.090 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 409 | 0.090 |
Why?
|
| Drug Monitoring | 2 | 2018 | 962 | 0.090 |
Why?
|
| Seafood | 2 | 2005 | 395 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 251 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 5789 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2019 | 385 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 157 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2014 | 762 | 0.090 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 311 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 740 | 0.090 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 338 | 0.090 |
Why?
|
| Self Report | 2 | 2020 | 3771 | 0.090 |
Why?
|
| Postmenopause | 2 | 2010 | 2517 | 0.090 |
Why?
|
| Massachusetts | 4 | 2021 | 8891 | 0.090 |
Why?
|
| Energy Intake | 5 | 2023 | 2142 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3609 | 0.090 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 452 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 932 | 0.090 |
Why?
|
| Blood Glucose | 3 | 2010 | 6422 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2012 | 307 | 0.090 |
Why?
|
| Aging | 2 | 2007 | 8731 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2013 | 2190 | 0.090 |
Why?
|
| Observer Variation | 2 | 2016 | 2614 | 0.080 |
Why?
|
| Tendinopathy | 1 | 2012 | 174 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2014 | 1966 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 7609 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2015 | 1160 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2023 | 4427 | 0.080 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 2392 | 0.080 |
Why?
|
| Serine | 1 | 2013 | 828 | 0.080 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 742 | 0.080 |
Why?
|
| Cell Death | 1 | 2014 | 1676 | 0.080 |
Why?
|
| Tendon Injuries | 1 | 2012 | 329 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 3757 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 2045 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 1319 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1946 | 0.080 |
Why?
|
| Office Visits | 1 | 2013 | 593 | 0.080 |
Why?
|
| Mice | 10 | 2021 | 81889 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3799 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2017 | 10445 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1627 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1241 | 0.070 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15416 | 0.070 |
Why?
|
| Sulfones | 2 | 2016 | 447 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2198 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 3246 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 1740 | 0.070 |
Why?
|
| Protein Methyltransferases | 1 | 2007 | 53 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2007 | 12150 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2234 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2014 | 1442 | 0.070 |
Why?
|
| Body Composition | 1 | 2017 | 2441 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 292 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4056 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2012 | 619 | 0.070 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 501 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5795 | 0.070 |
Why?
|
| Creatinine | 2 | 2010 | 1917 | 0.070 |
Why?
|
| Kansas | 2 | 2005 | 37 | 0.070 |
Why?
|
| Depression | 3 | 2022 | 8228 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2017 | 1581 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 1065 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 20144 | 0.070 |
Why?
|
| Smad6 Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
| Wine | 1 | 2007 | 172 | 0.070 |
Why?
|
| Neoplasms | 3 | 2023 | 22350 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 208 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 1604 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 1089 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 2056 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2827 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 8045 | 0.070 |
Why?
|
| Cell Line | 2 | 2024 | 15563 | 0.070 |
Why?
|
| Oocytes | 2 | 2024 | 1168 | 0.070 |
Why?
|
| Alleles | 3 | 2014 | 6895 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 1547 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 1145 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14471 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2017 | 2085 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2013 | 1065 | 0.060 |
Why?
|
| Iodide Peroxidase | 1 | 2007 | 295 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1161 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 1897 | 0.060 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 260 | 0.060 |
Why?
|
| Cell Movement | 3 | 2015 | 5199 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 2801 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2015 | 1417 | 0.060 |
Why?
|
| Yogurt | 1 | 2005 | 71 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 2902 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2009 | 2659 | 0.060 |
Why?
|
| Sepsis | 1 | 2019 | 2604 | 0.060 |
Why?
|
| Methylation | 1 | 2007 | 1074 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 8621 | 0.060 |
Why?
|
| Mitochondria | 1 | 2017 | 3677 | 0.060 |
Why?
|
| Beer | 1 | 2024 | 135 | 0.060 |
Why?
|
| Blood Pressure Determination | 2 | 2019 | 646 | 0.060 |
Why?
|
| Phosphofructokinase-2 | 1 | 2023 | 33 | 0.060 |
Why?
|
| Labyrinth Diseases | 1 | 2005 | 151 | 0.060 |
Why?
|
| Direct Service Costs | 1 | 2003 | 61 | 0.050 |
Why?
|
| General Practitioners | 2 | 2016 | 103 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2021 | 4018 | 0.050 |
Why?
|
| Probability | 3 | 2007 | 2476 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2010 | 6329 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2513 | 0.050 |
Why?
|
| Lung Neoplasms | 4 | 2015 | 13485 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 2463 | 0.050 |
Why?
|
| Osteitis Deformans | 1 | 2003 | 54 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6307 | 0.050 |
Why?
|
| Biological Availability | 1 | 2004 | 387 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 6558 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 582 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2007 | 1638 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1805 | 0.050 |
Why?
|
| Observation | 1 | 2004 | 310 | 0.050 |
Why?
|
| Mass Screening | 1 | 2018 | 5454 | 0.050 |
Why?
|
| Arthrography | 1 | 2003 | 149 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3110 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7841 | 0.050 |
Why?
|
| Educational Status | 1 | 2010 | 2510 | 0.050 |
Why?
|
| Anthropometry | 1 | 2007 | 1336 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 896 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3232 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 2 | 2020 | 1365 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2024 | 411 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2009 | 1319 | 0.050 |
Why?
|
| Telemedicine | 1 | 2019 | 3111 | 0.050 |
Why?
|
| Milk | 1 | 2005 | 436 | 0.050 |
Why?
|
| Mutation | 3 | 2016 | 30213 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2012 | 6214 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 1660 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 13643 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 172 | 0.050 |
Why?
|
| Diet Records | 1 | 2023 | 425 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 106 | 0.050 |
Why?
|
| Health Surveys | 2 | 2012 | 4055 | 0.050 |
Why?
|
| International Cooperation | 2 | 2020 | 1434 | 0.050 |
Why?
|
| Malondialdehyde | 1 | 2021 | 113 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2021 | 166 | 0.050 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 168 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2013 | 3429 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2020 | 2921 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2017 | 4735 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2024 | 9357 | 0.040 |
Why?
|
| Biological Transport | 1 | 2024 | 2083 | 0.040 |
Why?
|
| Nausea | 1 | 2022 | 681 | 0.040 |
Why?
|
| Albumins | 1 | 2022 | 578 | 0.040 |
Why?
|
| Vancomycin | 1 | 2022 | 504 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2010 | 2645 | 0.040 |
Why?
|
| Vomiting | 1 | 2022 | 652 | 0.040 |
Why?
|
| Exercise | 2 | 2021 | 5945 | 0.040 |
Why?
|
| ROC Curve | 1 | 2007 | 3620 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9525 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2003 | 458 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 376 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 110 | 0.040 |
Why?
|
| Cross Infection | 1 | 2008 | 1427 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 1996 | 0.040 |
Why?
|
| Electronics | 1 | 2020 | 315 | 0.040 |
Why?
|
| Asthma | 1 | 2017 | 6268 | 0.040 |
Why?
|
| Phototherapy | 1 | 2021 | 368 | 0.040 |
Why?
|
| Polynesia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Plant Proteins | 1 | 2020 | 375 | 0.040 |
Why?
|
| Causality | 1 | 2004 | 1252 | 0.040 |
Why?
|
| Endpoint Determination | 2 | 2011 | 592 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 14072 | 0.040 |
Why?
|
| Microcirculation | 1 | 2023 | 1282 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5700 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 1055 | 0.040 |
Why?
|
| Primates | 1 | 2020 | 519 | 0.040 |
Why?
|
| Organic Anion Transport Protein 1 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Color | 1 | 2019 | 297 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 3616 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 284 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9244 | 0.030 |
Why?
|
| Environment | 1 | 2003 | 1120 | 0.030 |
Why?
|
| Pharmacists | 1 | 2019 | 261 | 0.030 |
Why?
|
| Asia | 1 | 2019 | 629 | 0.030 |
Why?
|
| Uncertainty | 1 | 2022 | 764 | 0.030 |
Why?
|
| Histones | 1 | 2007 | 2593 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 685 | 0.030 |
Why?
|
| Income | 1 | 2005 | 1875 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2015 | 6976 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2023 | 1602 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 3804 | 0.030 |
Why?
|
| Mental Health | 2 | 2022 | 3270 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 165 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2019 | 3957 | 0.030 |
Why?
|
| Synovitis | 1 | 2017 | 217 | 0.030 |
Why?
|
| Infectious Disease Medicine | 1 | 2016 | 50 | 0.030 |
Why?
|
| Species Specificity | 1 | 2020 | 2413 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 795 | 0.030 |
Why?
|
| Food | 1 | 2020 | 764 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 682 | 0.030 |
Why?
|
| Microscopic Polyangiitis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 1425 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 3432 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 1203 | 0.030 |
Why?
|
| Veterans | 1 | 2009 | 2667 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 6222 | 0.030 |
Why?
|
| Leupeptins | 1 | 2015 | 112 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 686 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 1935 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 707 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2017 | 12430 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 811 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6962 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 2839 | 0.030 |
Why?
|
| Water | 1 | 2021 | 1417 | 0.030 |
Why?
|
| Goals | 1 | 2020 | 717 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2016 | 228 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12985 | 0.030 |
Why?
|
| Medical Records | 2 | 2014 | 1408 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 874 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 223 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2354 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2936 | 0.030 |
Why?
|
| State Medicine | 1 | 2015 | 219 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3314 | 0.030 |
Why?
|
| Acute Disease | 1 | 2024 | 7241 | 0.030 |
Why?
|
| Synovial Fluid | 1 | 2015 | 391 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 719 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 2881 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 1099 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 638 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 578 | 0.030 |
Why?
|
| Reference Values | 1 | 2020 | 4913 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 270 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2017 | 541 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2016 | 1251 | 0.030 |
Why?
|
| Inhibins | 1 | 2012 | 210 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2005 | 3618 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2141 | 0.020 |
Why?
|
| Vimentin | 1 | 2013 | 257 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2013 | 147 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2741 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 1892 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1606 | 0.020 |
Why?
|
| Internationality | 1 | 2017 | 1006 | 0.020 |
Why?
|
| Pedigree | 2 | 2014 | 4539 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2002 | 3576 | 0.020 |
Why?
|
| Data Collection | 2 | 2011 | 3321 | 0.020 |
Why?
|
| Homeostasis | 1 | 2023 | 3342 | 0.020 |
Why?
|
| Drug Repositioning | 1 | 2013 | 246 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3100 | 0.020 |
Why?
|
| China | 1 | 2017 | 2383 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2015 | 1882 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2023 | 4508 | 0.020 |
Why?
|
| Eosinophils | 1 | 2016 | 952 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 444 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 439 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2221 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3824 | 0.020 |
Why?
|
| Child | 3 | 2009 | 80668 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2017 | 702 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2015 | 684 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 181 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2232 | 0.020 |
Why?
|
| NF-kappa B | 2 | 2010 | 2493 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3139 | 0.020 |
Why?
|
| Glycolysis | 1 | 2014 | 838 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2015 | 960 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2017 | 5022 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 1495 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 902 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2077 | 0.020 |
Why?
|
| Androgens | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Apoptosis | 2 | 2014 | 9513 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 2744 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 3138 | 0.020 |
Why?
|
| Decision Making | 1 | 2002 | 3951 | 0.020 |
Why?
|
| Neurology | 1 | 2016 | 785 | 0.020 |
Why?
|
| Cadherins | 1 | 2013 | 902 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 2392 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2017 | 5992 | 0.020 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2008 | 52 | 0.020 |
Why?
|
| Photography | 1 | 2011 | 536 | 0.020 |
Why?
|
| Temperature | 1 | 2014 | 2233 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 1889 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2006 | 61 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 75 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 621 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 1941 | 0.020 |
Why?
|
| Proteins | 1 | 2021 | 6002 | 0.020 |
Why?
|
| Dermatology | 1 | 2016 | 905 | 0.020 |
Why?
|
| Neck Pain | 1 | 2008 | 190 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 1659 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 4780 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 210 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2016 | 2559 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2021 | 3459 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 3624 | 0.020 |
Why?
|
| Homocysteine | 1 | 2009 | 638 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6104 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2006 | 26389 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 729 | 0.020 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 241 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4276 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6512 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 1131 | 0.020 |
Why?
|
| Urinalysis | 1 | 2007 | 369 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 4670 | 0.010 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2008 | 304 | 0.010 |
Why?
|
| Psychiatry | 1 | 2016 | 1715 | 0.010 |
Why?
|
| Genomics | 1 | 2020 | 5923 | 0.010 |
Why?
|
| Patient Selection | 1 | 2016 | 4252 | 0.010 |
Why?
|
| Back Pain | 1 | 2008 | 547 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36567 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 36461 | 0.010 |
Why?
|
| Meniere Disease | 1 | 2005 | 164 | 0.010 |
Why?
|
| Binding Sites | 1 | 2012 | 6012 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3692 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 527 | 0.010 |
Why?
|
| Bone Density | 1 | 2016 | 3491 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 11920 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1663 | 0.010 |
Why?
|
| Fibromyalgia | 1 | 2008 | 407 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2003 | 216 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1790 | 0.010 |
Why?
|
| Cell Survival | 1 | 2013 | 5748 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 42577 | 0.010 |
Why?
|
| Base Sequence | 1 | 2014 | 12415 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2931 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2534 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 21162 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3561 | 0.010 |
Why?
|
| Skin | 1 | 2016 | 4499 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22352 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2013 | 4032 | 0.010 |
Why?
|
| Efficiency | 1 | 2005 | 479 | 0.010 |
Why?
|
| Tunica Media | 1 | 2002 | 107 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3001 | 0.010 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 41 | 0.010 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2002 | 32 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 10067 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3420 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1926 | 0.010 |
Why?
|
| Cryoglobulinemia | 1 | 2002 | 84 | 0.010 |
Why?
|
| Computational Biology | 1 | 2013 | 3564 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3666 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3531 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 326 | 0.010 |
Why?
|
| Cytokines | 1 | 2016 | 7438 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 844 | 0.010 |
Why?
|
| Pediatrics | 1 | 2016 | 3614 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1791 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9547 | 0.010 |
Why?
|
| New England | 1 | 2003 | 1059 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2002 | 455 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8735 | 0.010 |
Why?
|
| Arteritis | 1 | 2002 | 160 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9346 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 4891 | 0.010 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2005 | 783 | 0.010 |
Why?
|
| Models, Biological | 1 | 2015 | 9461 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2006 | 2001 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2012 | 5091 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 1027 | 0.010 |
Why?
|
| Outpatients | 1 | 2005 | 1596 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 1899 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 1469 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 3342 | 0.010 |
Why?
|
| Drug Costs | 1 | 2003 | 1195 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2429 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 6850 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2003 | 2520 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 18984 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6550 | 0.000 |
Why?
|